Use of Angiotensin II Inhibitors in Patients That Develop Encapsulating Peritoneal Sclerosis.

摘要

Encapsulating peritoneal sclerosis (EPS) is a rare but severe complication of peritoneal dialysis (PD) (1). Several risk factors for EPS, such as long-term PD, a high glucose Load, and peritonitis, have been proposed (2). Neoangiogenesis and peritoneal fibrosis are important features in the development of EPS (3). However, we still do not know how the development of EPS in PD patients can be prevented.